A previous study showed that CD44 increases the resistance of osteosarcoma cells to doxorubicin by upregulating the levels of MDR1 protein expression, and that deletion of CD44 leads to doxorubicin-dependent p53 activation and a profound Perp upregulation [85]. Here, CD44 is linked to osteosarcoma.